Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.
about
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal CancerExamination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsA phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors.Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapyCorrelation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage.Predictive Value of Early Skin Rash in Cetuximab-Based Therapy of Advanced Biliary Tract Cancer.
P2860
Q33434339-3E9FA941-940A-40EE-90D0-3BC8680C9315Q33823686-24C0E5F3-515D-4044-AE21-963DA110F2D7Q34008793-4DFA5679-63C4-4707-BD66-5E6836FA3D5BQ36200313-AC875F36-2034-4AF2-8CB3-548D2539CA96Q40494116-FD87F111-BB9B-44E2-827E-74A0412F485BQ42180652-89E8165A-C7B0-4DB3-BF91-35869DDBE8C4Q45175942-BA047FE8-9EC4-4D12-8EC8-2CC8C1A2BD1EQ46164559-A259A570-C7EF-420B-B010-8FD5AE44D1FDQ48214785-58353CFB-6304-46CB-BA9B-6C3E3F57100E
P2860
Pharmacogenetics of irinotecan: An ethnicity-based prediction of irinotecan adverse events.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@ast
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@en
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@nl
type
label
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@ast
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@en
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@nl
prefLabel
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@ast
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@en
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@nl
P2860
P356
P1476
Pharmacogenetics of irinotecan ...... of irinotecan adverse events.
@en
P2093
Shouji Shimoyama
P2860
P356
10.4240/WJGS.V2.I1.14
P577
2010-01-01T00:00:00Z